ClinicalTrials.gg
Active, not recruitingNCT04225117Updated Sep 23, 2026Results posted

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

A Phase 2 interventional study of enfortumab vedotin and pembrolizumab in Locally Advanced or Metastatic Malignant Solid Tumors, sponsored by Astellas Pharma Global Development, Inc.. Active, not recruiting at 39 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
329
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 645 studies in Triple Negative Breast Neoplasms with a site in United States — 163 open to participants now, 264 under way, 16 of them phase 3. Triple Negative Breast Neoplasms · United States.

Enrollment
57th of 605
329 · median 52
Started
2020
with 41 others
Phase 2
191 of 645
45 open now
Primary completion
2025-02
later than 30 of 263 live
Registered
352nd of 645
by date

Among the 645 studies in Triple Negative Breast Neoplasms with a site in United States, this one is the 57th largest by enrollment of the 605 interventional ones that give a count, is one of 42 that started in 2020, is one of 191 in phase 2, reaches primary completion later than 30 of the 263 other live ones, and was the 352nd registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

163 of the 645 studies in Triple Negative Breast Neoplasms with a site in United States are open now. Recruiting first, the newest first:

158 more — sign in →

All 163 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Triple Negative Breast Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed objective response rate (ORR) per RECIST v1.1.

This study will also assess other measures of antitumor activity; overall survival (OS); as well as the safety and tolerability of enfortumab vedotin for cohorts 1 to 8 and enfortumab vedotin + pembrolizumab in cohort 9.

Read the detailed description

This study will consist of 3 periods: screening/baseline, treatment and follow-up.

Screening/baseline period will take place up to 28 days prior to the first dose of study treatment.

In the treatment period, starting at cycle 1, participants in cohorts 1 to 8 will receive enfortumab vedotin on days 1, 8, and 15 every 28-day cycle until one of the treatment discontinuation criteria are met. participants in cohort 9 will receive enfortumab vedotin on days 1, 8, and pembrolizumab on day 1 of every 21-day cycle until one of the treatment discontinuation criteria are met. Disease assessment will be performed at screening/baseline and repeated every 8 weeks (56 days ± 7 days) for cohorts 1 to 8 and first assessment at week 9 and thereafter every 6 weeks (42 days ± 7 days) for cohort 9 from the first dose of study treatment throughout the study until the participant has radiologically confirmed disease progression, initiates a new subsequent anticancer therapy, dies, withdraws consent, is lost to follow-up or the study closes, whichever occurs first.

Participants who discontinue study treatment for reasons other than radiologically-confirmed disease progression by RECIST Version 1.1 will enter into a post treatment follow-up period and continue to receive imaging scans every 8 weeks (56 days ± 7 days) for cohorts 1 to 8 and for cohort 9 first scan will be performed at 9 week and thereafter every 6 weeks (42 days ± 7 days) until the subject has radiologically confirmed disease progression (for cohort 9 confirmed progressive disease [iCPD] per modified RECIST 1.1 for immune-based therapeutics [iRECIST]), initiates a new anticancer therapy, dies, withdraws consent, is lost to follow-up or the study closes, whichever occurs first.

After 1 year on study treatment, the frequency of disease assessment will be reduced to every 12 weeks (84 days ± 7 days) for cohorts 1 to 8.

After 18 months on study treatment, the frequency of disease assessment will be reduced to every 9 weeks (63 days ± 7 days) for cohort 9.

Participants in cohorts 1to 8 who discontinue study treatment for reasons other than radiologically-confirmed disease progression by RECIST Version 1.1 will enter into a post treatment follow-up period and continue to receive imaging scans every 8 weeks (56 days ± 7 days).

Participants in cohort 9 who discontinue study treatment for reasons other than radiologically confirmed disease progression per iRECIST will enter into a post treatment follow-up period and have physical exams, ECOG and disease assessments every 6 weeks (± 7 days) up to 18 months after first dose, then every 9 weeks (± 7 days) until the subject has radiologically confirmed disease progression per iRECIST.

After radiologically-confirmed disease progression or initiation of subsequent anticancer therapy, whichever occurs first, participants will be contacted every 12 weeks in the long-term follow-up period for survival status until death, withdrawal of consent, lost to follow-up or study closure, whichever occurs first.

03

Conditions studied

  • Locally Advanced or Metastatic Malignant Solid Tumors

Keywords

  • Squamous NSCLC
  • Triple negative breast cancer (TNBC)
  • ASG-22CE
  • non-small cell lung cancer (NSCLC)
  • Hormone receptor-positive/ human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer
  • non-squamous NSCLC
  • locally advanced or metastatic malignant solid tumors
  • Head and neck cancer
  • EV-202
  • Gastric or gastroesophageal junction (GEJ) or esophageal cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is considered an adult according to local regulation at the time of signing the form (ICF).
  • Subject has by Version 1.1.
  • Subject has accessible from either the primary tumor or a site, for which source and availability have been confirmed prior to study treatment. If no archival tumor tissue is available, the subject will have a biopsy to obtain tumor tissue prior to study treatment. If the subject is unable to undergo a biopsy due to safety concerns, enrollment into the study must be discussed with the medical monitor.
  • For cohort 9 only: Subject should submit archival or fresh tumor tissue sample for programmed cell death-ligand 1 () central testing during screening if no local PD-L1 test result is available. Central test result for PD-L1 will be required prior to subject enrollment. For cohort 9 subjects with local PD-L1 test result confirming CPS ≥ 1, archival or fresh tissue sample for exploratory analysis should be submitted within 5 days of enrollment.
  • Subject has performance status of 0 or 1.
  • Subject has the following baseline laboratory data. If a subject has received a recent blood transfusion, the hematology tests must be obtained ≥ 28 days after any blood transfusion.

    • (ANC) ≥ 1.0 × 10\^9/L
    • count ≥ 100 × 10\^9/L
    • ≥ 9 g/dL
    • serum total ≤ 1.5 × (ULN) or ≤ 3 × ULN for subjects with Gilbert's disease
    • (CrCl) ≥ 30 mL/min as estimated per institutional standards or as measured by 24-hour urine collection ( [GFR] can also be used instead of CrCl).
    • (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN
  • Subject agrees not to participate in another interventional study while receiving study treatment in the present study.
  • Additional requirements exist for male and female subjects.

Disease Specific Inclusion Criteria:

  • Evidence of progression on or after the last regimen received.
  • Locally advanced or metastatic disease that is not amenable to curative intent treatment.

Cohort 1: HR+/- breast cancer

  • Subject has evidence of radiographic progression on or after the last regimen received.
  • Subject has - or cytologically-confirmed HR+/HER2- (estrogen receptor [ER] positive and/or progesterone receptor [PR] positive, and HER2 negative) breast cancers and are not considered a candidate for further hormonal therapy. Subject will be considered HR+ if biopsies show ≥ 1% expression of ER or PR as per current American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines.
  • Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.
  • Subject must have received a taxane or anthracycline in the , adjuvant or incurable, locally advanced or metastatic setting.

    • Prior cytotoxic regimen received in the neoadjuvant or adjuvant setting will count as a prior cytotoxic regimen if disease recurrence occurred during or within 6 months of completing the regimen.
  • Subject has progressed, , or discontinued for toxicity during or after at least 1 prior standard of care cytotoxic regimen in the incurable, unresectable locally advanced or metastatic setting, and has not received > 2 prior lines of cytotoxic therapy in the locally advanced or metastatic setting. No limit applies to endocrine therapies. Poly(ADP-ribose) polymerases (PARP) inhibitors do not count as a line of cytotoxic therapy.
  • Subject has progressed, relapsed, or discontinued for toxicity during or after receiving endocrine therapy or with hormonally-directed therapy with cyclin-dependent kinase (CDK) inhibitors. Prior therapy with CDK inhibitors is not required.

Cohort 2: triple negative breast cancer (TNBC)

  • Subject has evidence of radiographic progression on or after the last regimen received.
  • Subject has histologically- or cytologically-confirmed TNBC; defined as unequivocal TNBC histology (ER-negative/PR-negative/HER2-negative). This is defined by \< 1% expression of ER and PR by immunohistochemistry (IHC), and that are, for HER2, either 0 to 1+ by IHC, or IHC 2+ and fluorescence in situ hybridization (FISH) negative (not amplified) as per current ASCO/CAP guidelines.
  • Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.
  • Subject must have received a taxane or anthracycline in the neoadjuvant, adjuvant or incurable, locally advanced or metastatic setting.

    • Prior cytotoxic regimen received in the neoadjuvant or adjuvant setting will count as a prior cytotoxic regimen if disease recurrence occurred during or within 6 months of completing the regimen.
  • Subject has progressed, relapsed, or discontinued for toxicity during or after at least 1 prior standard of care cytotoxic regimen in the incurable, unresectable locally advanced or metastatic setting, and has not received > 2 prior lines of cytotoxic therapy in the locally advanced or metastatic setting. Poly(ADP-ribose) polymerases (PARP) inhibitors do not count as a line of cytotoxic therapy.
  • Subject has received prior therapy with an anti-programmed cell death protein-1 (PD-1) or an anti-programmed cell death-ligand 1 (PD-L1) based on subject's tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed or discontinued treatment due to toxicity, or therapy is for subject.

Cohort 3: squamous non-small cell lung cancer (NSCLC)

  • Subject has evidence of radiographic progression on or after the last regimen received.
  • Subject has histologically or cytologically-confirmed squamous NSCLC.

    • Subjects with mixed histology NSCLC are eligible provided there is not any component of neuroendocrine histology.
    • Subjects with known epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), reactive oxygen species (ROS), BRAF, or other actionable mutations are eligible if treated with mutation targeted therapy and have progressed, relapsed, or discontinued treatment due to toxicity.
  • Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.
  • Subject has progressed, relapsed, or discontinued treatment due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received > 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.

    1. Subjects with locally advanced disease who previously received curative intent treatment with platinum-based standard of care regimen in the adjuvant or neoadjuvant setting or as part of concomitant chemoradiation therapy are eligible if they have progressed or relapsed within 6 months of completion.
    2. Maintenance therapy does not constitute a new chemotherapy regimen provided there was no progression after the initial platinum-based regimen.
    3. Changing chemotherapy agents during platinum-based treatment for the management of toxicities does not constitute a new chemotherapy regimen provided no progression had occurred while on the initial therapy.
  • Subject has received prior therapy with an anti-PD-1 or anti-PD-L1 based on subject's tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed, relapsed, or discontinued treatment due to toxicity, or therapy is contraindicated for subject.

Cohort 4: non-squamous non-small cell lung cancer

  • Subject has evidence of radiographic progression on or after the last regimen received.
  • Subject has histologically- or cytologically-confirmed non-squamous NSCLC.

    • Subjects with mixed histology NSCLC are eligible provided there is not any component of neuroendocrine histology.
    • Subjects with known EGFR, ALK, ROS, BRAF, or other actionable mutations are eligible if treated with mutation targeted therapy and have progressed, relapsed, or discontinued treatment due to toxicity.
  • Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.
  • Subject has progressed, relapsed, or discontinued treatment due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received > 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.

    1. Subjects with locally advanced disease who previously received curative intent treatment with platinum-based standard of care regimen in the adjuvant or neoadjuvant setting or as part of concomitant chemoradiation therapy are eligible if they have progressed or relapsed within 6 months of completion.
    2. Maintenance therapy does not constitute a new chemotherapy regimen provided there was no progression after the initial platinum-based regimen.
    3. Changing chemotherapy agents during platinum-based treatment for the management of toxicities does not constitute a new chemotherapy regimen provided no progression has occurred while on the initial therapy.
  • Subject has received prior therapy with an anti-PD-1 or anti-PD-L1 based on subject's tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed, relapsed, or discontinued treatment due to toxicity, or therapy is contraindicated for subject.

Cohort 5: or later head and neck cancer

  • Subject has evidence of radiographic progression on or after the last regimen received.
  • Subject has histologically- or cytologically-confirmed head and neck cancer.

    • Primary tumor site must arise from the oral cavity, oropharynx, hypopharynx, and larynx; tumors arising from the nasopharynx are excluded. Salivary gland tumors and/or parotid gland tumors are not eligible for Cohort 5.
  • Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.
  • Subject has progressed, relapsed, or discontinued treatment due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received > 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.

    • Subjects with locally advanced disease who previously received curative intent treatment with platinum-based standard of care regimen in the adjuvant or neoadjuvant setting or as part of concomitant chemoradiation therapy are eligible if they have progressed or relapsed within 6 months after completion.
  • Subject has received prior therapy with an anti-PD-1 or anti-PD-L1 based on subject's tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed, relapsed, or discontinued treatment due to toxicity, or therapy is contraindicated for subject.

Cohorts 6, 7 and 8: gastric or gastroesophageal junction (GEJ) or esophageal adenocarcinoma

  • Subject has evidence of radiographic progression on or after the last regimen received.
  • Subject has histologically- or cytologically-confirmed gastric, GEJ, or esophageal cancer.
  • Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.
  • Subject has progressed, relapsed, or discontinued due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received > 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.

    • Neoadjuvant or adjuvant cytotoxic regimens will count as a prior regimen if relapsed or progressed ≤ 6 months after completion.
  • Subject must have received a HER2 directed therapy if known to have HER2 positive cancer.
  • Subject has received prior therapy with an anti-PD-1 or anti-PD-L1 based on subject's tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed, relapsed, or discontinued treatment due to toxicity, or therapy is contraindicated for subject.

Cohort 9: 1L HNSCC

  • Subject has histologically- or cytologically-confirmed head and neck squamous cell carcinoma.

    a. Primary tumor site must arise from the oral cavity, oropharynx, hypopharynx, and larynx; tumors arising from the nasopharynx are excluded. Salivary gland tumors and/or parotid gland tumors are not eligible for Cohort 9.

  • Subject has recurrent or metastatic disease that is incurable by local therapies.
  • Subject's tumor sample has PD-L1 combined positive score (CPS) of ≥ 1 as determined by local or central IHC testing.
  • Subject has had no prior systemic therapy administered with the exception of systemic therapy completed > 6 months prior if given as part of multimodal treatment for locally advanced disease. Subjects who have received a PD-1 or PD-L1 inhibitor in the curative setting are eligible if it has been at least 12 months since last dose of the anti PD-L1 agent.
  • Subject has ANC ≥ 1.5 × 10\^9/L.
  • (INR) OR prothrombin time (PT) and activated partial thromboplastin (aPTT) both ≤ 1.5 × ULN unless subject is receiving anticoagulant therapy as long as PT or aPTT is within the therapeutic range of intended use of anticoagulants. PTT may be used if local lab is unable to perform aPTT.
  • For subjects with oropharynx tumors, subject has results from testing of HPV status by p16 testing.

Exclusion criteria

Exclusion Criteria:

For All Cohorts:

  • Subject has preexisting sensory or motor neuropathy Grade ≥ 2.
  • Subject has active central nervous system (CNS) . Subjects with treated are permitted on study if all the following are true:

    • CNS metastases have been clinically stable for ≥ 6 weeks prior to screening
    • If requiring treatment for CNS metastases, the subject is on a stable dose ≤ 20 mg/day of prednisone or equivalent for ≥ 2 weeks
    • Baseline imaging scans show no evidence of new or enlarged brain metastasis
    • Subject does not have
  • Subject has ongoing toxicity (Grade 2 or higher with the exception of alopecia) associated with prior treatment (including systemic therapy, radiotherapy or surgery).
  • Subjects with ongoing ≥ Grade 3 immunotherapy-related hypothyroidism or panhypopituitarism are excluded. Subjects with ongoing immunotherapy-related colitis, uveitis, myocarditis or pneumonitis, or subjects with other immunotherapy-related AEs requiring high doses of steroids (> 20 mg/day of prednisone or equivalent), are excluded. Subject with ≤ Grade 2 immunotherapy-related hypothyroidism or panhypopituitarism may be enrolled when well maintained/controlled on a stable dose of hormone replacement therapy (if indicated).
  • Subject has a history of uncontrolled diabetes mellitus within 3 months before the first dose of study treatment. Uncontrolled diabetes (within 3 months before first dose) is defined as (HbA1c) ≥ 8% or HbA1c between 7 and \< 8% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained. The lowest HbA1c during the screening period will be used to determine eligibility.
  • Subject has prior treatment with enfortumab vedotin or other monomethyl auristatin E (MMAE) based antibody-drug conjugates (ADCs).
  • Subject has a second diagnosed within 3 years before first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Subjects with non-melanoma skin cancer, localized prostate cancer treated with curative intent with no evidence of progression, low-risk or very low-risk (per standard guidelines) localized prostate cancer under active surveillance/watchful waiting without intent to treat, or carcinoma in situ of any type (if complete resection was performed) are allowed.
  • Subject is currently receiving systemic antimicrobial treatment for viral, bacterial, or fungal infection at the time of first dose of study treatment. Routine antimicrobial prophylaxis is permitted.
  • Subject has known active (e.g., hepatitis B surface antigen [HBsAg] reactive) or active (e.g., hepatitis C virus [HCV] RNA [qualitative] is detected).
  • Subject has known history of (HIV) infection (HIV 1 or 2).
  • Subject has documented history of a cerebral vascular event (stroke or ), unstable angina, myocardial infarction or cardiac symptoms (including congestive heart failure) consistent with Class III-IV within 6 months prior to the first dose of study drug.
  • Subject has major surgery within 4 weeks prior to first dose of study drug.
  • Subject had radiotherapy, chemotherapy, biologics, agents, and/or antitumor treatment with immunotherapy that is not completed 2 weeks prior to first dose of study drug.
  • Subject has known to enfortumab vedotin or to any contained in the drug formulation of enfortumab vedotin (including histidine, trehalose dihydrate and polysorbate 20) OR subject has known hypersensitivity to biopharmaceutical produced in Chinese hamster ovary cells.
  • Subject has known active keratitis or corneal ulcerations. Subject with superficial punctate keratitis is allowed if the disorder is being adequately treated.
  • Subject has any condition which makes the subject unsuitable for study participation.

Cohort 9: 1L HNSCC

  • Had PD within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC.
  • Has had an allogeneic tissue/solid organ transplant. Has severe hypersensitivity (≥grade 3) to pembrolizumab and/or any of its excipients.
  • Has a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease.
  • Has a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.
  • Has a of less than 3 months and/or has rapidly progressing disease (e.g. tumor bleeding, uncontrolled tumor pain) in the opinion of the treating investigator.
  • Active disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or drugs).

    1. Replacement therapy (e.g., thyroxine, insulin, physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
    2. Brief (\<7 days) use of systemic corticosteroids is allowed when use is considered standard of care.
    3. Subjects with vitiligo, psoriasis, type 1 diabetes mellitus, hypothyroidism, or resolved childhood asthma/atopy will not be excluded.
    4. Subjects requiring intermittent use of bronchodilators, inhaled steroids, or local steroid injections will not be excluded.
    5. Subjects with hypothyroidism that is stable with hormone replacement or Sjögren's syndrome will not be excluded.
  • Has an active infection requiring systemic therapy.
  • Has received prior therapy with an or anti-PD-L1 agent in the recurrent/metastatic setting. If anti-PD-1 or anti-PD-L1 agent was given as part of curative intent therapy, it must be at least 1 year since last dose.
  • Has received a within 30 days of planned start of study therapy. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.
  • Subject has active tuberculosis
Terms in these criteria, in plain language(41)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
329 participants (actual)

Study arms

  • Experimental
    Cohort 1: HR+/HER2- breast cancer

    Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle. HR+/HER2- = Hormone receptor-positive/ human epidermal growth factor receptor 2-negative

    Drug: enfortumab vedotin

  • Experimental
    Cohort 2: Triple negative breast cancer (TNBC)

    Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.

    Drug: enfortumab vedotin

  • Experimental
    Cohort 3: Squamous non-small cell lung cancer

    Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.

    Drug: enfortumab vedotin

  • Experimental
    Cohort 4: Non-squamous non-small cell lung cancer

    Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.

    Drug: enfortumab vedotin

  • Experimental
    Cohort 5: Head and neck cancer

    Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.

    Drug: enfortumab vedotin

  • Experimental
    Cohort 6: Gastric or GEJ or esophageal cancer

    Participants enrolled into Cohort 6 will be reallocated based on disease type and histology into Cohorts 7 or 8. GEJ= gastroesophageal junction

    Drug: enfortumab vedotin

  • Experimental
    Cohort 7: Gastric and esophageal adenocarcinoma (EAC) including GEJ adenocarcinoma

    Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.

    Drug: enfortumab vedotin

  • Experimental
    Cohort 8: Esophageal squamous cell carcinoma (ESCC)

    Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.

    Drug: enfortumab vedotin

  • Experimental
    Cohort 9: Head and neck squamous cell carcinoma (HNSCC)

    Participants will receive enfortumab vedotin as an IV infusion on days 1 and 8 of each 21-day cycle. Pembrolizumab will be administered as an IV infusion on day 1 of each 21-day cycle.

    Drug: enfortumab vedotin · Drug: pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Cohorts 1-8: Confirmed Overall Response Rate (ORR) (Complete Response [CR] and Partial Response [PR]) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (V)1.1 Per Investigator Assessment

    Confirmed ORR was defined as the percentage of participants whose objective response was confirmed as CR or PR according to RECIST V1.1 per investigator assessment, using exact method based on binomial distribution (Clopper-Pearson).

    Time frame: Up to 20.04 months

  2. Cohort 9: Confirmed ORR (CR and PR) Per RECIST V1.1 Per Investigator Assessment

    Confirmed ORR was defined as the percentage of participants whose objective response was confirmed as CR or PR according to RECIST V1.1 per investigator assessment, using exact method based on binomial distribution (Clopper-Pearson).

    Time frame: Up to 12.85 months

Secondary outcomes

  1. Cohorts 1-8: Duration of Resonse (DOR) Per RECIST V.1.1 Per Investigator Assessment

    DOR was defined as the time from the date of first documented response (CR or PR that is subsequently confirmed) to the date of first documented progressive disease (PD) per RECIST V1.1 or death due to any cause, whichever occurs first. DOR was only calculated for participants achieving a confirmed CR or PR, based on Kaplan-Meier estimate.

    Time frame: Up to 20.04 months

  2. Cohorts 1-8: Disease Control Rate (DCR) Per RECIST V1.1 Per Investigator Assessment

    DCR was defined as the percentage of participants whose Best Overall Response (BOR) was confirmed CR or PR or stable disease (SD) (≥ 7 weeks).

    Time frame: Up to 22 months

  3. Cohorts 1-8: Progression Free Survival (PFS) Per RECIST V1.1 Per Investigator Assessment

    PFS was defined as the time from start of study intervention to first documentation of objective tumor progression or death due to any cause, whichever comes first, based on Kaplan-Meier estimate.

    Time frame: Up to 22 months

  4. Cohorts 1-8: Overall Survival (OS)

    OS was defined as the time from start of study treatment to date of death due to any cause, based on Kaplan-Meier estimate. In the absence of confirmed death, OS was censored at the last date the participant was known to be alive.

    Time frame: Up to 34 months

  5. Cohorts 1-8: Number of Participants With Treatment-emergent Adverse Events (AEs)

    A TEAE is any untoward medical occurrence in a participant administered enfortumab vedotin, and which does not necessarily have to have a causal relationship with this treatment. A TEAE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of enfortumab vedotin whether or not considered related to the enfortumab vedotin. A TEAE is considered "serious" if the event: results in death; is life-threatening; results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions; results in congenital anomaly or birth defect; requires inpatient hospitalization (except for planned procedures) or leads to prolongation of hospitalization (except if prolongation of planned hospitalization is not caused by a TEAE); or other medically important events.

    Time frame: Up to end of treatment + 30 days (32 months)

  6. Cohort 9: DOR Per RECIST V.1.1 Per Investigator Assessment

    DOR was defined as the time from the date of first documented response (CR or PR that is subsequently confirmed) to the date of first documented PD per RECIST V1.1 or death due to any cause, whichever occurs first. DOR was only calculated for participants achieving a confirmed CR or PR, based on Kaplan-Meier estimate.

    Time frame: Up to 12.85 months

  7. Cohort 9: DCR Per RECIST V1.1 Per Investigator Assessment

    DCR was defined as the percentage of participants whose BOR is confirmed CR or PR or SD (≥ 7 weeks).

    Time frame: Up to 15 months

  8. Cohort 9: PFS Per RECIST V1.1 by Investigator Assessment

    PFS was defined as the time from start of study intervention to first documentation of objective tumor progression or death due to any cause, whichever comes first, based on Kaplan-Meier estimate.

    Time frame: Up to 15 months

  9. Cohort 9: OS

    OS was defined as the time from start of study treatment to date of death due to any cause, based on Kaplan-Meier estimate. In the absence of confirmed death, OS was censored at the last date the participant was known to be alive.

    Time frame: Up to 15.4 months

  10. Cohort 9: Number of Participants With TEAEs

    A TEAE is any untoward medical occurrence in a participant administered enfortumab vedotin, and which does not necessarily have to have a causal relationship with this treatment. A TEAE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of enfortumab vedotin whether or not considered related to the enfortumab vedotin. A TEAE is considered "serious" if the event: results in death; is life-threatening; results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions; results in congenital anomaly or birth defect; requires inpatient hospitalization (except for planned procedures) or leads to prolongation of hospitalization (except if prolongation of planned hospitalization is not caused by an AE); or other medically important events.

    Time frame: Up to end of treatment + 30 day (15 months)

07

Results

Posted Apr 13, 2026

Participant flow

Participants of either gender, over 18 years of age, who were either previously treated for locally advanced or metastatic malignant solid tumours (Cohorts 1-8) or who had no previous treatment (Cohort 9), were enrolled in this study. Cohort 9 enrolment began after protocol amendment 5 was implemented.

Participant flow — Overall Study
MilestoneCohort 1: HR+/HER2- Breast CancerCohort 2: TNBC CancerCohort 3: Squamous NSCLCCohort 4: Non-squamous NSCLCCohort 5: Head and Neck CancerCohort 7: EACCohort 8: ESCCCohort 9: HNSCC
Started4542234546424541
Completed00000000
Not completed4542234546424541
Withdrew: Did not receive any amount of study intervention00020010
Withdrew: Withdrawal by subject47224832
Withdrew: Lost to follow-up11140010
Withdrew: Death363020333734399
Withdrew: Miscellaneous00001000
Withdrew: Ongoing440440130

Outcome measures

PrimaryCohorts 1-8: Confirmed Overall Response Rate (ORR) (Complete Response [CR] and Partial Response [PR]) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (V)1.1 Per Investigator Assessment

Confirmed ORR was defined as the percentage of participants whose objective response was confirmed as CR or PR according to RECIST V1.1 per investigator assessment, using exact method based on binomial distribution (Clopper-Pearson).

Time frame:
Up to 20.04 months
Reported as:
Number · Percentage of participants
Cohorts 1-8: Confirmed Overall Response Rate (ORR) (Complete Response [CR] and Partial Response [PR]) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (V)1.1 Per Investigator Assessment
Percentage of participantsCohort 1: HR+/HER2- Breast CancerCohort 2: TNBC CancerCohort 3: Squamous NSCLCCohort 4: Non-squamous NSCLCCohort 5: Head and Neck CancerCohort 7: EACCohort 8: ESCC
Cohorts 1-8: Confirmed Overall Response Rate (ORR) (Complete Response [CR] and Partial Response [PR]) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (V)1.1 Per Investigator Assessment15.6 (6.49 to 29.46)19.0 (8.60 to 34.12)4.3 (0.11 to 21.95)16.3 (6.81 to 30.70)23.9 (12.59 to 38.77)9.5 (2.66 to 22.62)18.2 (8.19 to 32.71)
PrimaryCohort 9: Confirmed ORR (CR and PR) Per RECIST V1.1 Per Investigator Assessment

Confirmed ORR was defined as the percentage of participants whose objective response was confirmed as CR or PR according to RECIST V1.1 per investigator assessment, using exact method based on binomial distribution (Clopper-Pearson).

Time frame:
Up to 12.85 months
Reported as:
Number · Percentage of participants
Cohort 9: Confirmed ORR (CR and PR) Per RECIST V1.1 Per Investigator Assessment
Percentage of participantsCohort 9: HNSCC
Cohort 9: Confirmed ORR (CR and PR) Per RECIST V1.1 Per Investigator Assessment39.0 (24.20 to 55.50)
SecondaryCohorts 1-8: Duration of Resonse (DOR) Per RECIST V.1.1 Per Investigator Assessment

DOR was defined as the time from the date of first documented response (CR or PR that is subsequently confirmed) to the date of first documented progressive disease (PD) per RECIST V1.1 or death due to any cause, whichever occurs first. DOR was only calculated for participants achieving a confirmed CR or PR, based on Kaplan-Meier estimate.

Time frame:
Up to 20.04 months
Reported as:
Median · Months
Cohorts 1-8: Duration of Resonse (DOR) Per RECIST V.1.1 Per Investigator Assessment
MonthsCohort 1: HR+/HER2- Breast CancerCohort 2: TNBC CancerCohort 3: Squamous NSCLCCohort 4: Non-squamous NSCLCCohort 5: Head and Neck CancerCohort 7: EACCohort 8: ESCC
Cohorts 1-8: Duration of Resonse (DOR) Per RECIST V.1.1 Per Investigator Assessment7.23 (3.52 to 7.23)3.78 (1.87 to 3.94)3.71 (NA to NA)10.15 (9.69 to 10.38)9.43 (2.53 to NA)10.32 (1.64 to 10.32)3.88 (2.33 to 7.39)
SecondaryCohorts 1-8: Disease Control Rate (DCR) Per RECIST V1.1 Per Investigator Assessment

DCR was defined as the percentage of participants whose Best Overall Response (BOR) was confirmed CR or PR or stable disease (SD) (≥ 7 weeks).

Time frame:
Up to 22 months
Reported as:
Number · Percentage of participants
Cohorts 1-8: Disease Control Rate (DCR) Per RECIST V1.1 Per Investigator Assessment
Percentage of participantsCohort 1: HR+/HER2- Breast CancerCohort 2: TNBC CancerCohort 3: Squamous NSCLCCohort 4: Non-squamous NSCLCCohort 5: Head and Neck CancerCohort 7: EACCohort 8: ESCC
Cohorts 1-8: Disease Control Rate (DCR) Per RECIST V1.1 Per Investigator Assessment51.1 (35.77 to 66.30)57.1 (40.96 to 72.28)65.2 (42.73 to 83.62)67.4 (51.46 to 80.92)56.5 (41.11 to 71.07)47.6 (32.00 to 63.58)45.5 (30.39 to 61.15)
SecondaryCohorts 1-8: Progression Free Survival (PFS) Per RECIST V1.1 Per Investigator Assessment

PFS was defined as the time from start of study intervention to first documentation of objective tumor progression or death due to any cause, whichever comes first, based on Kaplan-Meier estimate.

Time frame:
Up to 22 months
Reported as:
Median · Months
Cohorts 1-8: Progression Free Survival (PFS) Per RECIST V1.1 Per Investigator Assessment
MonthsCohort 1: HR+/HER2- Breast CancerCohort 2: TNBC CancerCohort 3: Squamous NSCLCCohort 4: Non-squamous NSCLCCohort 5: Head and Neck CancerCohort 7: EACCohort 8: ESCC
Cohorts 1-8: Progression Free Survival (PFS) Per RECIST V1.1 Per Investigator Assessment5.39 (3.35 to 5.68)3.52 (2.10 to 4.63)3.52 (1.91 to 5.42)4.11 (2.76 to 5.72)3.94 (2.79 to 4.67)3.06 (1.77 to 3.71)2.10 (1.87 to 3.71)
SecondaryCohorts 1-8: Overall Survival (OS)

OS was defined as the time from start of study treatment to date of death due to any cause, based on Kaplan-Meier estimate. In the absence of confirmed death, OS was censored at the last date the participant was known to be alive.

Time frame:
Up to 34 months

Results for this outcome have not been posted.

SecondaryCohorts 1-8: Number of Participants With Treatment-emergent Adverse Events (AEs)

A TEAE is any untoward medical occurrence in a participant administered enfortumab vedotin, and which does not necessarily have to have a causal relationship with this treatment. A TEAE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of enfortumab vedotin whether or not considered related to the enfortumab vedotin. A TEAE is considered "serious" if the event: results in death; is life-threatening; results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions; results in congenital anomaly or birth defect; requires inpatient hospitalization (except for planned procedures) or leads to prolongation of hospitalization (except if prolongation of planned hospitalization is not caused by a TEAE); or other medically important events.

Time frame:
Up to end of treatment + 30 days (32 months)
Reported as:
Count of participants · Participants
Cohorts 1-8: Number of Participants With Treatment-emergent Adverse Events (AEs)
ParticipantsCohort 1: HR+/HER2- Breast CancerCohort 2: TNBC CancerCohort 3: Squamous NSCLCCohort 4: Non-squamous NSCLCCohort 5: Head and Neck CancerCohort 7: EACCohort 8: ESCC
TEAEs45422242454243
Serious TEAEs129816221412
SecondaryCohort 9: DOR Per RECIST V.1.1 Per Investigator Assessment

DOR was defined as the time from the date of first documented response (CR or PR that is subsequently confirmed) to the date of first documented PD per RECIST V1.1 or death due to any cause, whichever occurs first. DOR was only calculated for participants achieving a confirmed CR or PR, based on Kaplan-Meier estimate.

Time frame:
Up to 12.85 months
Reported as:
Median · Months
Cohort 9: DOR Per RECIST V.1.1 Per Investigator Assessment
MonthsCohort 9: HNSCC
Cohort 9: DOR Per RECIST V.1.1 Per Investigator AssessmentNA (5.78 to NA)
SecondaryCohort 9: DCR Per RECIST V1.1 Per Investigator Assessment

DCR was defined as the percentage of participants whose BOR is confirmed CR or PR or SD (≥ 7 weeks).

Time frame:
Up to 15 months
Reported as:
Number · Percentage of participants
Cohort 9: DCR Per RECIST V1.1 Per Investigator Assessment
Percentage of participantsCohort 9: HNSCC
Cohort 9: DCR Per RECIST V1.1 Per Investigator Assessment75.6 (59.70 to 87.64)
SecondaryCohort 9: PFS Per RECIST V1.1 by Investigator Assessment

PFS was defined as the time from start of study intervention to first documentation of objective tumor progression or death due to any cause, whichever comes first, based on Kaplan-Meier estimate.

Time frame:
Up to 15 months
Reported as:
Median · Months
Cohort 9: PFS Per RECIST V1.1 by Investigator Assessment
MonthsCohort 9: HNSCC
Cohort 9: PFS Per RECIST V1.1 by Investigator Assessment5.06 (3.45 to NA)
SecondaryCohort 9: OS

OS was defined as the time from start of study treatment to date of death due to any cause, based on Kaplan-Meier estimate. In the absence of confirmed death, OS was censored at the last date the participant was known to be alive.

Time frame:
Up to 15.4 months

Results for this outcome have not been posted.

SecondaryCohort 9: Number of Participants With TEAEs

A TEAE is any untoward medical occurrence in a participant administered enfortumab vedotin, and which does not necessarily have to have a causal relationship with this treatment. A TEAE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of enfortumab vedotin whether or not considered related to the enfortumab vedotin. A TEAE is considered "serious" if the event: results in death; is life-threatening; results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions; results in congenital anomaly or birth defect; requires inpatient hospitalization (except for planned procedures) or leads to prolongation of hospitalization (except if prolongation of planned hospitalization is not caused by an AE); or other medically important events.

Time frame:
Up to end of treatment + 30 day (15 months)

Results for this outcome have not been posted.

Adverse events

Collected over Cohorts 1-8: All-cause mortality: up to 34 months; AEs: up to end of treatment + 30 days (32 months). Cohort 9: All-cause mortality: up to 15 months; AEs: up to end of treatment + 30 days (15 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: HR+/HER2- Breast Cancer36/45 (80%)12/45 (26.7%)44/45 (97.8%)
Cohort 2: TNBC Cancer30/42 (71.4%)9/42 (21.4%)42/42 (100%)
Cohort 3: Squamous NSCLC20/23 (87%)8/23 (34.8%)21/23 (91.3%)
Cohort 4: Non-squamous NSCLC33/45 (73.3%)16/43 (37.2%)42/43 (97.7%)
Cohort 5: Head and Neck Cancer38/46 (82.6%)22/46 (47.8%)42/46 (91.3%)
Cohort 7: EAC34/42 (81%)14/42 (33.3%)41/42 (97.6%)
Cohort 8: ESCC39/45 (86.7%)12/44 (27.3%)42/44 (95.5%)
Cohort 9: HNSCC10/41 (24.4%)21/41 (51.2%)39/41 (95.1%)
Most frequent serious events
Showing 10 of 135
Most frequent serious events
EventCohort 1: HR+/HER2- Breast CancerCohort 2: TNBC CancerCohort 3: Squamous NSCLCCohort 4: Non-squamous NSCLCCohort 5: Head and Neck CancerCohort 7: EACCohort 8: ESCCCohort 9: HNSCC
COVID-19Infections and infestations0/450/422/231/430/460/421/440/41
Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/450/420/230/430/460/421/443/41
SyncopeNervous system disorders0/450/420/230/430/460/420/443/41
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/450/421/232/430/460/420/443/41
Abdominal painGastrointestinal disorders2/450/420/230/431/462/420/442/41
SepsisInfections and infestations2/451/420/232/430/460/420/442/41
Acute kidney injuryRenal and urinary disorders0/450/421/231/430/461/420/442/41
Pleural effusionRespiratory, thoracic and mediastinal disorders0/451/420/230/431/460/420/442/41
Disease progressionGeneral disorders0/450/420/230/430/462/420/440/41
Alanine aminotransferase increasedInvestigations1/452/420/230/430/460/420/440/41
Most frequent other events
Showing 10 of 100
Most frequent other events
EventCohort 1: HR+/HER2- Breast CancerCohort 2: TNBC CancerCohort 3: Squamous NSCLCCohort 4: Non-squamous NSCLCCohort 5: Head and Neck CancerCohort 7: EACCohort 8: ESCCCohort 9: HNSCC
FatigueGeneral disorders21/4513/4212/2316/4314/4615/429/4419/41
Decreased appetiteMetabolism and nutrition disorders9/4511/4211/2313/4310/4616/4213/449/41
PruritusSkin and subcutaneous tissue disorders20/4515/428/2317/437/4617/4213/4416/41
Rash maculo-papularSkin and subcutaneous tissue disorders19/4514/426/2316/438/4612/4213/4410/41
Peripheral sensory neuropathyNervous system disorders7/4511/426/2317/4313/466/425/449/41
AlopeciaSkin and subcutaneous tissue disorders11/4513/429/2316/4313/4615/428/4412/41
NauseaGastrointestinal disorders17/4515/428/2315/438/4613/429/4413/41
DiarrhoeaGastrointestinal disorders12/455/428/2312/4311/4612/422/4415/41
ConstipationGastrointestinal disorders10/456/426/239/437/4615/428/448/41
DysgeusiaNervous system disorders13/4513/428/2314/439/4614/4211/446/41

Baseline characteristics

Full Analysis Set (FAS): All enrolled participants who received any amount of study intervention.

Age, Continuous
Age, Continuous(Years)Cohort 1: HR+/HER2- Breast CancerCohort 2: TNBC CancerCohort 3: Squamous NSCLCCohort 4: Non-squamous NSCLCCohort 5: Head and Neck CancerCohort 7: EACCohort 8: ESCCCohort 9: HNSCCTotal
Mean57.5 ± 9.853.5 ± 11.365.5 ± 8.565.7 ± 10.463.2 ± 9.559.5 ± 1264.9 ± 966.5 ± 7.961.8 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: HR+/HER2- Breast CancerCohort 2: TNBC CancerCohort 3: Squamous NSCLCCohort 4: Non-squamous NSCLCCohort 5: Head and Neck CancerCohort 7: EACCohort 8: ESCCCohort 9: HNSCCTotal
Female45421021612810154
Male00132240303631172
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: HR+/HER2- Breast CancerCohort 2: TNBC CancerCohort 3: Squamous NSCLCCohort 4: Non-squamous NSCLCCohort 5: Head and Neck CancerCohort 7: EACCohort 8: ESCCCohort 9: HNSCCTotal
Hispanic or Latino4101040212
Not Hispanic or Latino4040224143374038301
Unknown or Not Reported1111314113
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: HR+/HER2- Breast CancerCohort 2: TNBC CancerCohort 3: Squamous NSCLCCohort 4: Non-squamous NSCLCCohort 5: Head and Neck CancerCohort 7: EACCohort 8: ESCCCohort 9: HNSCCTotal
American Indian or Alaska Native000000000
Asian711391511389103
Native Hawaiian or Other Pacific Islander000000000
Black or African American4212100212
White322517312729229192
More than one race010000001
Unknown or Not Reported2321324118
08

Study locations

39 sites
09

References and documents

Publications

  • Muro K, Feinstein T, Baranda J, Bonta I, Yanagitani N, Gersten T, Gandhi L, Kudo T, Fujioka N, Kaplan J, Gorla S, Liu S, Wozniak M, Poondru S, Dillon R, Meng C, Patil T. Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study. Eur J Cancer. 2025 Sep 9;227:115603. doi: 10.1016/j.ejca.2025.115603. Epub 2025 Jul 9. PubMed 40819431 ↗
  • Swiecicki PL, Yilmaz E, Rosenberg AJ, Fujisawa T, Bruce JY, Meng C, Wozniak M, Zhao Y, Mihm M, Kaplan J, Gorla S, Geiger JL. Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer. J Clin Oncol. 2025 Feb 10;43(5):578-588. doi: 10.1200/JCO.24.00646. Epub 2024 Oct 31. PubMed 39481054 ↗
  • Muro K, Chin K, Maron SB, Braiteh FS, Mitani S, Hara H, Kuboki Y, Mulcahy MF, Baranda JC, Gardner FP, Jin N, Hamauchi S, Kaplan J, Gorla S, Liu S, Wozniak M, Poondru S, Dillon R, Meng C, Kondo S. Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers. ESMO Open. 2025 Nov;10(11):105806. doi: 10.1016/j.esmoop.2025.105806. Epub 2025 Oct 23. PubMed 41135379 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Feb 2025, 59 months.

Results were first posted in Apr 2026, 1 year 1 month after primary completion.

Of 255 phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 94. This study's 59 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2020
First posted
Jan 13, 2020
StartActual
Mar 10, 2020
Primary completionActual
Feb 25, 2025
CompletionEst.
Mar 31, 2027
Results first posted
Apr 13, 2026
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04225117
Responsible party
Sponsor
First posted
Jan 13, 2020
Start date
Mar 10, 2020
Primary completion
Feb 25, 2025
Completion
Mar 31, 2027 (estimated)
Results posted
Apr 13, 2026
Last update
Sep 23, 2026

Study contacts

Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enfortumab vedotin

Start the discussion